Abstract
A 60-year-old man diagnosed with macular telangiectasia type 1 (MacTel 1) was treated for 3 years with monthly aflibercept (Eylea; Regeneron, Tarrytown, NY) and serially imaged with spectral-domain optical coherence tomography. When administered monthly, aflibercept appeared to have a beneficial effect on macular edema secondary to MacTel 1. Visual acuity preservation despite minimal chronic macular edema could be attributed to the lack of significant photoreceptor disruption. [Ophthalmic Surg Lasers Imaging Retina. 2016;47:593-595.].
Copyright 2016, SLACK Incorporated.
Publication types
-
Case Reports
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Fluorescein Angiography / methods*
-
Follow-Up Studies
-
Fundus Oculi
-
Humans
-
Intravitreal Injections
-
Macula Lutea / pathology*
-
Macular Edema / diagnosis
-
Macular Edema / drug therapy*
-
Macular Edema / etiology
-
Male
-
Middle Aged
-
Receptors, Vascular Endothelial Growth Factor / administration & dosage*
-
Receptors, Vascular Endothelial Growth Factor / antagonists & inhibitors
-
Recombinant Fusion Proteins / administration & dosage*
-
Retinal Telangiectasis / complications
-
Retinal Telangiectasis / diagnosis
-
Retinal Telangiectasis / drug therapy*
-
Time Factors
-
Tomography, Optical Coherence / methods*
-
Visual Acuity*
Substances
-
Recombinant Fusion Proteins
-
aflibercept
-
Receptors, Vascular Endothelial Growth Factor